Condition: IgA Nephropathy (IgAN) · Sponsor: Biocity Biopharmaceutics Co., Ltd.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of SC0062 capsule compared to placebo in patients with IgA nephropathy in the presence of proteinuria. The participants must have a high risk of disease progression, despite of stable use of the maximum tolerated labelled or optimized dose of RAASi and/or SGLT2i for at least 12 weeks prior to randomization.
This description comes directly from the study's public registry record.
Yu Xueqing, Prof · 020-838-27812 · yuxueqing@gdph.org.cn
Ye Zhiming, Prof · 86+13826161678 · Yezhiming@gdph.org.cn
Always discuss trial participation with your own doctor first.
| Guangdong Provincial People's Hospital | Guangzhou, Yuexiu District, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06819826